GDGiulia D'ARcangelo

Giulia D'ARcangelo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Giulia D'ARcangelo has a total of 126 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pediatric inflammatory bowel diseases in patients with genetic syndromes: A case–control multicentre SIGENP study

    by Francesca Di Sario, Chiara Monachesi, Enrico Felici, Sara Curto, Flavio Labriola, Licia Pensabene, Serena Arrigo, Chiara Longo, Francesca Penagini, Giovanna Zuin, et al.

    Objectives: To characterize the clinical phenotype and long‐term outcomes of pediatric inflammatory bowel disease (IBD) in patients with genetic syndromes. Methods: Multicenter observational case‐control study using data from the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition IBD registry. Patients diagnosed with pediatric‐onset IBD (p = 0.004) and height (−1.43 z ‐score, p < 0.001); these differences persisted at follow‐up. Diagnostic delay was longer in syndromic patients (+6.5 months, p = 0.045). Abdominal pain was less frequent at presentation ( p = 0.01). Syndromic patients had more hospitalizations (IBD‐related incidence rate ratio [IRR] 1.23, p = 0.033; non‐IBD IRR 1.65, p < 0.001), more comorbidities (odds ratio [OR] 18.2, p < 0.001), and greater use of non‐IBD medications (OR 8.17, p = 0.004). The risk of additional autoimmune diseases was higher but not statistically significant. Conclusions: Pediatric IBD patients with genetic syndromes show impaired growth and delayed diagnosis, while intestinal disease activity and treatment exposure are comparable to non‐syndromic peers. The higher burden of comorbidities and hospitalizations indicates greater healthcare complexity and diagnostic challenges; early recognition and coordinated multidisciplinary care are reasonable clinical considerations, but their impact on outcomes requires prospective evaluation.

  • Current practices and unmet needs in the management of Clostridioides difficile infection in pediatric inflammatory bowel disease: A national survey

    by Anastasiia Romanchuk, Matteo Bramuzzo, Flavio Labriola, Marina Aloi, Claudia Banzato, Luca Bosa, Antonio Colucci, Mara Corpino, Rita Сozzali, Giulia D'ARcangelo, et al.

    Objectives: Children with inflammatory bowel disease (IBD) are at increased risk for Clostridioides difficile infection (CDI), which is associated with worse clinical outcomes. We aimed to assess current diagnostic and therapeutic practices for CDI among Italian pediatric IBD centers. Methods: A nationwide survey was conducted in 2025 using a structured 28‐item questionnaire distributed to all pediatric IBD centers in Italy. Items addressed diagnostic strategies, treatment approaches, recurrence management, and immunosuppressive therapy handling in children with IBD and CDI. Results: Twenty‐seven centers responded (response rate, 90%). Diagnostic approaches varied: toxin enzyme immunoassays (EIA) were indicated by 21/27 centers (78%), glutamate dehydrogenase (GDH) testing by 19/27 (70%), and nucleic acid amplification tests (NAAT) by 13/27 (48%). Routine CDI testing at IBD diagnosis was indicated by 12/27 centers (44%), whereas 23/27 (85%) reported testing during IBD flares. For a first non‐severe episode, vancomycin and metronidazole were equally identified as preferred first‐line options (18/27; 66% each). Oral vancomycin was the preferred treatment for recurrent CDI (26/27; 96%). Third or subsequent recurrences prompted consideration of fidaxomicin (19/27; 70%), fecal microbiota transplantation (6/27; 22%), and bezlotoxumab (2/27; 7%). In fulminant CDI, 7/27 centers (26%) indicated adding fidaxomicin to standard therapy. In acute severe colitis with concomitant CDI at diagnosis, 18/27 centers (67%) described a cautious approach to biologic initiation. Conclusions: This nationwide survey highlights substantial unmet needs in CDI management in pediatric IBD, including variability in diagnostic strategies, lack of consensus on first‐line therapy, and uncertainty regarding immunosuppressive management, supporting the need for evidence‐based pediatric‐specific guidelines.

  • Disorders of Gut-Brain Interaction-Like Symptoms in Children With Inflammatory Bowel Disease: A Multicenter Prospective Study From the Pediatric Inflammatory Bowel Disease Porto Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition

    by Massimo Martinelli, Simona Salomone, Caterina Strisciuglio, Aglaia Zellos, Claudio Romano, Valeria Dipasquale, Matteo Bramuzzo, Sara Lega, Marina Aloi, Giulia D'ARcangelo, et al.

    INTRODUCTION: Disorders of gut-brain interaction (DGBI) are frequently reported in patients with inflammatory bowel disease (IBD), but pediatric data are scarce. We aimed to determine the prevalence of DGBI-like symptoms in children with quiescent IBD compared with healthy controls (HC), and to evaluate their impact on health-related quality of life, anxiety and symptoms burden. METHODS: This multicenter, prospective, observational study enrolled children aged 10–18 years with biochemically quiescent IBD, with or without endoscopic confirmation of remission from 7 European Society of Pediatric Gastroenterology, Hepatology and Nutrition centers (January 2021–August 2023). Age and sex-matched HC were recruited through primary care pediatricians and screened for subclinical inflammation using fecal calprotectin. DGBI were assessed using Rome IV criteria. Health-related quality of life and psychological burden were evaluated using IMPACT III, PROMIS Anxiety, Visceral Sensitivity Index–Child, and Behavioral Response Questionnaire–Child. RESULTS: A total of 253 children were enrolled (IBD: n = 131; HC: n = 122). The prevalence of DGBI-like symptoms did not differ between IBD and HC (34.4% vs 41.8%, P = 0.30). Functional abdominal pain disorders were present in 24.4% of children with IBD. Children with IBD and DGBI-like symptoms showed significantly lower IMPACT III scores compared with those without DGBI [median 74 (interquartile range 62.5–81) vs 84 (70–90); P = 0.001], with the greatest impairment in IBD symptoms, energy, and social domains. PROMIS Anxiety scores were higher in the DGBI group [31 (20–44) vs 21.5 (16–28); P < 0.001], with a greater proportion exceeding the clinical threshold (>50) (17.8% vs 3.5%; P = 0.008). Female sex was the only independent predictor of DGBI (OR 5.2, 95% CI 1.6–16.1; P = 0.005). DISCUSSION: DGBI-like symptoms are common in children with quiescent IBD and are associated with a substantial psychological and quality-of-life burden.

  • Open Access

    Exploring novel biomarkers in pediatric ulcerative colitis: The role of Lipocalin-2, MMP-9, and MMP-9/LCN-2 complex

    by Giulia D'ARcangelo, Roberto Paparella, Alessandro Gravina, Francesca Tarani, Luigi Tarani, Marina Aloi, Carla Petrella


  • Open Access

    Diagnostic accuracy of non-invasive tests for helicobacter pylori infection in children: A multicenter retrospective study by SIGENP

    by Tonia Raso, Giulia D’aRcangelo, Sara Renzo, Caterina Strisciuglio, Antonio Colucci, Marco Deganello Saccomani, Matteo Bramuzzo, Francesca Bravin, Naire Sansotta, Giusy Russo, et al.


  • Is transmural healing better than mucosal healing in pediatric Crohn’s disease?

    by Giulia D'ARcangelo, Silvia Rotulo, Salvatore Oliva, Giusy Russo, Manuela Distante, Francesca Zucconi, Ludovica Busato, Carlo Catalano, Francesca Maccioni, Marina Aloi


  • Open Access

    Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group

    by Serena Arrigo, Patrizia Alvisi, Claudia Banzato, Matteo Bramuzzo, Rosaria Celano, Fortunata Civitelli, Giulia D'ARcangelo, Anna Dilillo, Valeria Dipasquale, Enrico Felici, et al.


  • Treat-to-Target in Pediatric Inflammatory Bowel Disease: What Does the Evidence Say?

    by Giulia D’aRcangelo, Marina Aloi

    The traditional management of inflammatory bowel disease, based on treatment intensification guided by clinical activity alone, has been revised in the last 10 years and a treat-to-target approach has been proposed and is currently under evaluation as a disease-modifying strategy. Treat-to-target focuses on objective and scheduled measures to monitor intestinal damage, with consequent therapeutic adjustments in case of failure to achieve pre-defined targets. Identification of targets has been set out by the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) committee in 2015. Mucosal healing is universally accepted as the main target both in Crohn’s disease and ulcerative colitis, given its proven association with better long-term outcomes than clinical remission alone. Equally important is to ensure patients’ clinical remission and improve patient-reported outcomes. Transmural healing (for Crohn’s disease) and histological remission (for ulcerative colitis), listed as adjunctive targets, are likely to become primary targets in the near future. The ultimate goal of this approach is to modify the natural history of inflammatory bowel diseases by trying to block bowel damage progression, with interventions in the pre-clinical stage. In this review, we will discuss the current recommended therapeutic targets, as well as those that are considered adjunctive targets, with a focus on the limited pediatric literature available. Prospective long-term trials are warranted in order to identify the most appropriate target for the pediatric population and its specific issues. Identification of reliable predictors of disease course, outcome, and response to treatment will help to individually adapt each step of this monitoring algorithm and consequent therapeutic decision.


  • Mucosal healing in Crohn’s disease: new insights

    by Salvatore Cucchiara, Giulia D’aRcangelo, Sara Isoldi, Marina Aloi, Laura Stronati

    Introduction. Traditional management of patients with Crohn’s disease includes symptoms and quality of life improvement. With the advent of biological agents, mucosal healing has become an achievable goal, documented through endoscopy. However, due to the transmural nature of inflammation, the prevention of bowel damage should be included in the aims of a targeted therapeutic strategy. Areas Covered. Updated literature has been searched in PubMed from 2008 to 2020. This review focuses on the state of the art in the innovative therapeutic goals in Crohn’s disease, also considering still controversial aspects and future research topics in the management of Crohn’s disease. Expert Opinion. Although a widely agreed view supports the notion that mucosal healing and bowel damage control may promote beneficial outcomes (i.e. reduction in hospitalization and surgical rates, avoidance of steroids), long term robust data are still missing. On the other hand, the development of -omics techniques have expanded our knowledge of the pathogenetic mechanism underlying inflammatory bowel disease and opened up new horizons in precision or personalized medicine.